Gilead Sciences 2012 Annual Report Download

Download and view the complete annual report

Please find the complete 2012 Gilead Sciences annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 13

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13

GILEAD SCIENCES ANNUAL REPORT 2012

Table of contents

  • Page 1
    GILEAD SCIENCES ANNUAL REPORT 2012

  • Page 2
    ... family and friends. Because she knows first-hand the importance of support for people facing serious health challenges, Katie plans to devote her career to helping those in need. She recently graduated from the University of Central Florida and aims to pursue a master's degree in public health. 3

  • Page 3
    ... the 2012 International AIDS Conference-the largest gathering of scientists, clinicians, public health experts and advocates committed to eradicating the disease-a sense of growing optimism prevailed. The approval of Truvada for PrEP was noted as a milestone that could help slow the spread of HIV in...

  • Page 4
    ... Auckland, New Zealand, is a leading expert on treating chronic hepatitis C. As the principal investigator of the ELECTRON study of Gilead's investigational agent sofosbuvir, Dr. Gane is excited by the potential of all-oral regimens that could make treatment more effective and tolerable for patients...

  • Page 5
    ..., she sees her role as an essential bridge between her patients and the often-complex clinical trial process. Tessa works closely with her patients to answer questions, explain research protocols and schedule study visits-all important steps in the search to find new treatments for today and in the...

  • Page 6
    ... Development and Chief Scientific Officer; Katie L. Watson, Senior Vice President, Human Resources; John F. Milligan, PhD, President and Chief Operating Officer HIV/AIDS Scientific advancements-in drug design, formulation and delivery-and public health advancements-in disease awareness, screening...

  • Page 7
    ... patients, and co-pay assistance coupon programs help those unable to afford the co-payments associated with commercial health insurance programs. Gilead is also expanding access to its medications in resource-limited parts of the world-including developing countries where the HIV/AIDS epidemic...

  • Page 8
    ... is to 10 11 12 10 11 12 develop a cure. Gilead scientists are engaged in earlystage research to identify novel therapeutic agents that may help eradicate HIV infection. EU MARKETING APPROVAL SUBMITTED STRIBILD® (ELVITEGRAVIR 150MG/COBICISTAT 150MG/ EMTRICITABINE 200MG/TENOFOVIR DISOPROXIL...

  • Page 9
    ... care and further define the clinical benefit of Letairis in broader patient populations. Diana Brainard, MD, Senior Director, Clinical Research, Liver Diseases, Gilead Sciences Phil Pang, MD, Director, Clinical Research, Liver Diseases, Gilead Sciences PHASE 2 SIMTUZUMAB* (MONOCLONAL ANTIBODY...

  • Page 10
    ... clinical trials for chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma. Momelotinib is an investigational JAK inhibitor that has shown promise for the treatment of myelofibrosis, a blood disorder. This molecule was added to Gilead's development pipeline through the acquisition of YM...

  • Page 11
    ...a long history of working with state AIDS Drug Assistance Programs (ADAPs) to increase access to HIV treatment. A voluntary price freeze and additional discounts for ADAPs for our HIV medicines run through 2013. ACCESS HIGHLIGHTS EMTRIVA® EMTRICITABINE HIV/AIDS JAPAN TOBACCO INC. (JAPAN) LETAIRIS...

  • Page 12
    ... diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Asia Pacific. AmBisome, Cayston, Complera, Emtriva, Eviplera, Gilead, Gilead Sciences, the Gilead logo design, Hepsera, Letairis, Ranexa, Stribild, Truvada, Viread, Vistide and Volibris...

  • Page 13
    GILEAD SCIENCES, INC. 333 LAKESIDE DRIVE FOSTER CITY, CALIFORNIA 94404 650 574 3000 T 800 445 3235 650 578 9264 F WWW.GILEAD.COM